Medtronic Adds Stimgenics’ Novel Pain Therapy To Intellis Spinal Cord Stimulator
Executive Summary
Medtronic acquired Stimgenics, an Illinois company it previously helped to fund, for an undisclosed sum. The company plans to add Stimgenics’ differential target multiplexed spinal cord stimulation waveform to its Intellis spinal cord stimulation system for the treatment of chronic pain.
You may also be interested in...
Long-Term Data Confirm Durability Of Medtronic’s DTM Back Pain Therapy
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.
NANS 2020: Medtronic’s DTM Spinal Cord Stimulation Relieves Back Pain In Trial
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
Brain Therapies Leads Medtronic’s Growth In First Quarter Of Fiscal 2020
The medtech giant reported revenue of $7.5bn in the quarter that ended on 26 July, up 3.5% year-over-year basis, led by 12.5% growth in revenues from emerging markets. Medtronic’s fastest-growing business is its brain therapies unit, which reported 11.4% growth in the quarter.